ѻý

Hair Relaxers' Cancer Risk; Genetic Test Aids Rural Care; Drug Negotiation Fallout?

<ѻý class="mpt-content-deck">— News, features, and commentary about cancer-related issues
MedpageToday
Onco Break over a computer rendering of a cancer cell.

Regular use of chemical hair relaxers by Black women increased their by 50%. (Boston University, Environmental Research)

Adding the immune activator BXCL701 to pembrolizumab (Keytruda) significantly improved median overall survival (OS) in as compared with single-agent pembrolizumab, BioXcel announced.

Bristol Myers Squibb added to its oncology portfolio with the $5.8 billion and the KRAS-targeted drug adagrasib (Krazati), as well as other promising oncology agents in the Mirati pipeline.

Perioperative pembrolizumab significantly improved OS in resectable stage II, IIIA, or IIIB , Merck announced.

An AI-driven tumor assessment system showed potential for of central nervous system tumors. (Nature)

of newly diagnosed breast cancer at a rural hospital informed changes in planned clinical management in 70% of cases. (Annals of Surgical Oncology)

The Drug Enforcement Agency has extended a COVID-era rule to allow without an in-person visit through December 2024.

, combined with the current Medicare reimbursement model, could have potentially dire financial consequences for community oncology practices. (JAMA Oncology)

The FDA cleared HistoSonics' for noninvasive treatment of liver tumors.

Aggressive surgery to remove as much tumor as possible in did not adversely affect patients' quality of life. (Journal of the National Comprehensive Cancer Network)

A distinguished between benign and malignant pelvic masses with greater than 90% accuracy in a preliminary clinical test. (University of Southern California, Clinical Cancer Research)

Mucositis after treatment for may occur more often than previously thought. (Roswell Park Comprehensive Cancer Center, JAMA Network Open)

An online questionnaire can help women quickly assess their and obtain information about risk reduction and other issues. (Dana-Farber Cancer Institute)

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined ѻý in 2007.